Search
BW-A 58C
go.drugbank.com/drugs/DB06740ExperimentalBW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy
QR-333
go.drugbank.com/drugs/DB05533InvestigationalQR-333 has been investigated as a treatment for diabetic peripheral neuropathy.
Taspoglutide
go.drugbank.com/drugs/DB14027InvestigationalAs of May 2013 no new trials had been registered.
Lecithin, soybean
go.drugbank.com/drugs/DB14161Investigationalcomplex mixture of phospholipids; glycolipids; and triglycerides; with substantial amounts of phosphatidylcholines; phosphatidylethanolamines; and phosphatidylinositols, which are sometimes loosely termed as
CIGB 2020 Vaccine
go.drugbank.com/drugs/DB15808ExperimentalAs of July, 2020, a Randomized control clinical trial (RPCEC00000306) is underway to evaluate prophylaxis potential in suspected contacts of Covid-19 patients.
Veru-111
go.drugbank.com/drugs/DB16462InvestigationalThese trials aimed to evaluate its efficacy, safety, and tolerability in conditions such as SARS-CoV-2 infection, metastatic castration-resistant prostate cancer (mCRPC), respiratory distress syndrome
Ramosetron
go.drugbank.com/drugs/DB09290InvestigationalIt is believed to have higher potency and longer antiemetic action than other 1st generation 5-HT3 antagonists such as ondansetron.
EVT 302
go.drugbank.com/drugs/DB06057InvestigationalEVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.
Radotinib
go.drugbank.com/drugs/DB12323InvestigationalRadotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Iberdomide
go.drugbank.com/drugs/DB12101Investigationaldrugs such as lenalidomide. … [L64055] Iberdomide has shown anti-tumor activity in multiple myeloma cells resistant to lenalidomide and pomalidomide, and as a CELMoD is designed to degrade Ikaros and Aiolos more potently than immunomodulatory